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The incidence of IBD is increasing worldwide, with a prevalence now approaching 0.5% in the West 2 . For patients with longstanding colonic inflammation, colorectal cancer (CRC) is a recognized and feared complication. Studies quantifying the increased risk of CRC in patients with IBD have generated vari able results reflecting differences in country of origin, study population and disease duration 3 . The first large meta analysis assessing CRC risk in patients with IBD showed a risk of 2% at 10 years after ulcerative colitis diagnosis, 8% at 20 years and 18% at 30 years after colitis onset 4 . However, other studies suggest that CRC rates in patients with ulcerative colitis might be declining 5 . Important clinical differences exist between colitis associated CRC (CACRC) arising in patients with IBD, compared with sporadic CRC seen in the general population. CACRCs tend to affect younger patients 6 (average age of 50-60 years in IBD 7, 8 compared with 65-75 years for sporadic CRCs in the general popula tion), they are more likely to be found in the proximal colon in the presence of Crohn's disease 9 or primary sclerosing cholangitis 10 , they are more commonly syn chronous (15-20% of CACRC 11, 12 compared with 3-5% of sporadic CRC) and have an increased frequency of mucinous or signet ring cell histology 13 . Patients with longstanding extensive colonic IBD are enrolled into surveillance programmes that aim to detect precursor colitisassociated dysplasia, a pre malignant equivalent of sporadic adenomas. In practice, detecting dysplasia at endoscopy can be challenging. These lesions are often flat with subtle borders that are difficult to appreciate in the presence of concomi tant inflammation; they might be readily missed in a background of extensive mucosal scarring and pseudo polyposis. Missed dysplasia might be a contributing factor in the stubbornly high rates of interval CACRCs that develop between scheduled endoscopies 14 . When dysplasia is detected, patient management remains fraught with challenges. The diagnosis of IBD associated dysplasia is confirmed through histo logical analysis with defining features including nuclear atypia, mucin depletion and an irregular crypt architecture with loss of basaltoluminal epithelial cell matur ation 15 . Immunohistochemical staining for markers including p53 and βcatenin are sometimes used to complement histological classification 16 . In practice, dysplasia grading suffers from substantial inter observer variability and can be challenging to differentiate from a regenerating epithelium 17 . With improved endoscopic 1 
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Abstract | Optimizing the management of colorectal cancer (CRC) risk in IBD requires a fundamental understanding of the evolutionary process underpinning tumorigenesis. In IBD, clonal evolution begins long before the development of overt neoplasia, and is probably accelerated by the repeated cycles of epithelial wounding and repair that are characteristic of the condition. Here, we review the biological drivers of mutant clone selection in IBD with particular reference to the unique histological architecture of the intestinal epithelium coupled with the inflammatory microenvironment in IBD, and the unique mutation patterns seen in IBD-driven neoplasia when compared with sporadic adenomas and CRC. How these data can be leveraged as evolutionary-based biomarkers to predict cancer risk is discussed, as well as how the efficacy of CRC surveillance programmes and the management of dysplasia can be improved. From a research perspective, the longitudinal surveillance of patients with IBD provides an under-exploited opportunity to investigate the biology of the human gastrointestinal tract over space and time.
imaging, areas of lowgrade and indefinite dysplasia are now detected in up to 10% of surveillance colono scopies 18 . Some patients with IBDassociated low grade dysplasia are offered more intensive surveillance, whereas others are offered the option of colectomy, with all the associated risks of major surgery and con sequences of life with a stoma. Data from the largest UK surveillance registry data has demonstrated that the 10year CRC risk from lowgrade dysplasia is only 30% 11 ; others have shown that lowgrade dysplasia regresses in at least half of patients 19 although the mech anism is unclear. Together, these findings indicate that the current primary aim of dysplasia identification in CRC surveillance is inadequate as a cancerrisk stratifi cation tool. A clear clinical need to better understand the molecular aetiology of CACRC remains, which would enable the identifi cation of more efficacious biomarkers of cancer risk. Recognizing the develop ment of CACRC as an evolution ary process prov ides a novel and powerful perspective to understand this disease, in a manner that can be directly lever aged to improve the clinical care of this challenging patient group. This Review will summarize the evidence support ing the presence of extensive inflammationdriven clonal evolution in IBD, long before the development of any clinically apparent neoplasia, and contrast this under standing with our current knowledge of sporadic CRC carcinogenesis. Finally, we discuss how knowledge of this occult evolutionary process can aid prognostication and ultimately improve the efficacy of IBDassociated cancer surveillance.
Evidence of clonal evolution in IBD Occult evolution in colitis Carcinogenesis is a process of clonal evolution [20] [21] [22] . Somatic cells acquire mutations that alter their pheno type, which might confer them and their progeny a growth and/or survival advantage within their cur rent microenvironment, enabling the cells to persist and clonally expand. A classic example is mutations of APC in the context of colorectal adenoma forma tion that result in persistent βcatenin signalling and increased cellular proliferation 23 . With the occurrence of further mutations, additional selection pressures and clonal expansion could occur. In some cases, this process eventually results in the development of a malignant phenotype.
In IBD, the clonal evolution of cancer begins long before the development of a true malignancy. Numerous studies, using a variety of different molecular techniques, have reported extensive genomic and epi genomic alter ations in morphologically normal intestinal mucosa (TABLE 1) . The surprisingly high mutation burden of the ostensibly normal IBD epithelium reveals the 'occult evolution' that is occurring in the inflamed bowel. These mutant clones clearly experience a pos itive selec tive pressure (mutants cells are fitter than non mutant cells) as they can expand to fill large areas of the intes tinal mucosa 24 and, in one extreme case, the entire colon length 25 . Mutant clones frequently bear mutations in key tumoursuppressor genes including TP53 (encod ing p53) and CDKN2A (encoding p16), and in the proto oncogene KRAS [24] [25] [26] [27] . Remarkably, these cancer associated mutations do not alone cause neo plastic growth as the mutations are detected in non neoplastic tissue [24] [25] [26] [27] . These 'key' mutations might be necessary but insufficient for tumour growth, or the phenotypic effects of these mutations are crit ically modu lated by epigenetic and/or microenviron mental constraints present in nonneoplastic mucosa. Nevertheless, the clonal expansion of these cancer associated mutants provides a genetic foundation for the phenomenon of 'field cancer ization' (REF. 28 ), which is the preconditioning of a large area of histologically nor mal epithelium to the future development of neoplastic lesions 29 (FIG. 1) . Field cancerization probably explains the high frequency of synchronous and metachronous neoplastic lesions in patients with IBD 11, 12 .
Inflammation accelerates evolution
The mutation burden in the morphologically normal nonIBD colon is not well characterised; however, the limited evidence available to date suggests that the nor mal mutation rate is less than in patients with IBD 30, 31 and that widespread clonal expansion of mutant cells is rare 32 . Consequently, the inflamed bowel appears to be a 'hot bed' of somatic clonal evolution, but the reasons why are currently unknown. Our hypothesis is that the evolutionary process in IBD is accelerated by longstanding repeated cycles of epithelial wounding and repair that are characteristic of IBD. Mechanistically, IBDassociated inflammation has the potential to mediate clonal evolution by any, or all, of the following three mechanisms: generating a mutagenic pressure; providing a selective advantage to those clones able to survive a (cytotoxic) inflammatory insult; providing a selective advantage to those clones able to more rapidly repopulate the healing mucosa.
DSS (dextran sodium sulfate)treated mice offer a unique opportunity to assess flat and polypoid dys plasia in a single animal model; both these lesions develop as a consequence of the induced chemical colitis. Here, the severity of inflammation correlates with the propen sity to generate IBDlike flat dysplastic lesions; inflam mation scores were an order of magnitude higher in colons containing flat dysplasia compared with those with polypoid dysplasia 33 . Moreover, administration of
Key points
• Colorectal cancer development in IBD begins many years before the development of neoplasia because of occult evolution within the inflamed bowel • The cycles of wounding and repair characteristic of IBD provide a selective pressure for mutant cells that are able to rapidly heal the mucosa and withstand the inflammatory insult • Measuring and modulating the occult evolutionary process offers new avenues for effectively predicting and preventing colorectal cancer in IBD • Repositories of IBD surveillance materials offer a surreptitious opportunity to study in vivo clonal evolution in time and space in humans 5aminosalicylates, the mainstay of treatment for ulcer ative colits, had a varying effect on the incidence and progression of dysplastic lesions on the basis of mor phology, with fewer flat lesions that were unchanged in size, but the same number of polypoid lesions that were reduced in size 34 . Patientbased studies confirm that inflammation has a substantial cumulative role in increasing CRC risk in IBD, with observational studies consistently demonstrat ing that CACRC risk development is closely linked to the extent 35 , duration 4 and severity of inflammation 7 . Histological studies suggest that neoplastic lesions arise from a field of marked chronic inflammation, telomere shortening, DNA damage and senescence, with 'escape from senescence' a key step in the transition from low grade to highgrade dysplasia 36 . Thus, a comprehensive understanding of carcinogenesis in IBD should not be limited to the study of mutation generation and spread via the epithelial crypt stem cell niche, but should also include a concomitant analysis of the inflammatory stro mal microenvironment. Therapeutic interventions that modulate cancer risk in IBD must target these aberrant microenvironmental changes.
In addition to native cells of the epithelial layer, immune cells and bacteria migrate up to the crypt as part of IBD pathogenesis, inducing a myriad of inflammatory cytokines and intracellular signalling pathways 1 that are beyond the scope of this Review 37 . These pathways act directly on nonneoplastic and dysplastic epithelial cells, which can potentially modulate cancer risk. Animal model studies demonstrate how transcription signal ling by NFκB -a master regulator of inflammation 38 that has a key role in IBD patho genesis 39 -promotes the survival of premalignant epithelial clones 40 . IBD mediated inflammation also promotes βcatenin stabil ity through aberrant PI3K-AKT 41, 42 and NFκB 43 signalling to further enhance canonical Wnt activity. Epithelial STAT3 signalling is also upregulated in active IBD 44 . Mouse models show that, although STAT3 path way activation helps amelior ate the effects of chemical colitis by reducing epithelial damage and inflam mation, it also promotes the survival and progression of pre malignant epithelial clones 45 . Conceivably, noncell autonomous effects similar to those identified in other systems (for example, in a breast cancer model 46 ) might also be involved. In this same context, the effect of an altered immune system in IBD on immunosurveil lance necessary to limit CRC initi ation and progression warrants further investigation. For example, CACRCs and dysplastic lesions show a greater infiltration of CD3 + and CD8
+ lymphocytes, but substantially less granzyme B expression than sporadic CRCs, suggesting impaired cytotoxic function 47 . Emerging studies in the field of microbiome analy sis are revealing the role of the gut microbiota and intestinal barrier function in tumorigenesis, and animal studies are beginning to shed some light onto the complex and dynamic interplay between the altered immune system, the aberrant gut microbiome and cancer development in IBD 37 . In practice, it remains difficult to determine whether intestinal dysbiosis and mucosal barrier changes drive mucosal pathology, or represent a secondary con sequence of disease. However, these options are not mutually exclusive. A prominent example comes from Arthur et al. 48 , who used Il10knockout mice to demon strate how chronic inflammation prevents the homeo static elimination of cancer associated Escherichia coli, inducing the upregulation of the polyketide synthase gene responsible for the genotoxic compound coli bactin. In turn, E. coli with genotoxic capabilities have been shown to drive tumorigenesis in this mouse model, in a manner independent of inflammation severity 49 . This effect is probably dependent on a breakdown in the mucosal barrier 50 , enabling the direct exposure of the epithelium to colibactin. Subsequent human stud ies confirm that colibactinequipped E. coli are mark edly more prevalent in colonic mucosa from patients with sporadic CRC and patients with ulcerative colitis compared with controls (patients with sporadic polyps or IBS) 49, 51 . Similarly, Fusobacterium have been found to promote tumorigenesis in animal models 52 and are over represented in both sporadic adenomas and CRC 53 , as well as in nonneoplastic IBD mucosa 54 . Finally, simi lar changes in colonic mucus affecting IBD, colon polyps and colon cancer have been described 55 . A prominent example is the re expression of the mucinassociated oncofoetal carbohydrate, sialylTnantigen, at higher rates in patients with ulcerative colitis who subsequently progress to dysplasia or cancer than those that remain cancerfree 56 . This increased expression seems to be independent of inflammation severity.
Somatic mutations in CA-CRC
The different evolutionary pressures offer an explan ation for the altered pattern of somatic mutations seen in CACRC compared with sporadic cancers 57, 58 . Available data show that CACRCs have increased muta tion frequencies of various intracellular and intercellu lar signalling molecules 57, 58 . The most notable mutations include IL16, a gene encoding a chemo attractant cytokine that is overexpressed in IBD in an inflamma tiondependent manner 59 . IL16 has a potential role in directly mediating inflammation 60 and so we specu late that a gene mutation encoding this protein could provide a survival advantage in the inflamed bowel. Another noteworthy mutation is in RADIL, a gene encoding a modulator of Rho GTPase signalling in cell migration, which might speculatively provide a selective advantage in mucosal healing 57 . Mutation signature analysis 61 of CACRCs 57 demon strate novel trinucleotide context changes not seen in sporadic CRCs (an overrepresentation of A>C trans versions at AA dinucleotides). The predominance of C>T transitions at CG dinucleotides in CACRCs is in keeping with 'accelerated ageing' through rapid cell turn over 62 rather than the accumulation of direct genotoxic hits caused by inflammationassociated carcinogens. Indeed, colitis that progresses to highgrade dysplasia or CACRC demonstrates field changes in ostensibly normal epithelium in keeping with accelerated age ing, including telomere shortening 36 and agerelated CpG methylation 63 . Although TP53 mutations are found at similar fre quencies in both sporadic CRC and CACRC, TP53 alteration is an early event in CACRC that is found in nontumour, and even nondysplastic, mucosa 64 . Indeed, accumulating evidence suggests a role for TP53 mutations in promoting cell survival and growth 65 . Interestingly, the increased frequency and early onset of TP53 mutations might provide an additional explan ation for the fairly high proportion of flat dysplastic and cancer ous lesions seen in IBD. One study 66 demonstrated a significant variability in neoplasm morphology that is dependent on Tp53 mutation status, with flat lesions associated with Tp53 −/− mice treated with DSS (~85% flat lesions), and polypoid lesions significantly associated with Tp53 +/− and Tp53 +/+ DSStreated mice (~17% flat lesions; P <0.0001).
Perhaps most notably, CACRCs in humans show a paucity of APC mutations 57,58 compared with sporadic adenomas and CRC, in which APC mutations are a common, important and early 'gatekeeper' event 67 . APC encodes a key regulator of the canonical Wnt pathway driving βcatenin signalling. Disruption of normal APC function is sufficient to constitutively activate this path way and initiate sporadic adenomas in the noninflamed bowel 67, 68 . The lack of APC mutations in colitis raises the possibility of IBDgenerated inflammationmediated alterations of underlying Wnt signalling cascades that render APC mutations dispensable for tumorigenesis. Indeed, immunostaining studies of colonic epithelium confirm high levels of Wnt signalling, as demonstrated by increased nuclear to cytoplasmic βcatenin levels in human ulcerative colitis tissue 69 . The βcatenin levels are midway between normal noninflamed epithelium and established CRC, thereby partially replicating the con stitutive canonical Wnt pathway activation of an APC mutation. Furthermore, wounding of the intestinal epi thelium induces a host of canonical and noncanonical Wnt signalling pathways by mesenchymal cells 70 . Aside from these pertinent genomic differences, the genomes of CACRCs and sporadic CRCs in humans interestingly show broad similarities. Both bear a high frequency of TP53 alteration and mutations in the onco genes KRAS, BRAF, PIK3CA, CTNNB1 and the tumour suppressors SMAD4 and FBXW7 are at relatively high, albeit slightly different, frequencies 57, 58, 71 . Microsatellite instability is also common to a subset of both cancer types 72, 73 . Together, these data imply some convergence in the outcome of evolutionary processes of sporadic CRC and CACRC development. Dysregulation of key pathways such as Wnt signalling and p53 function seem to be necessary for tumour formation in the colon, irrespec tive of the presence or absence of a (prior) inflammatory stimulus. Studies of clonal evolution at the level of the crypt are discussed in the next section, advancing our understanding of the survival advan tage these genomic changes provide, specifically in the context of IBDmediated inflammation.
Mechanisms of clonal expansion Colonic crypt architecture
The basic functional unit of the colon is the crypt, a finger like invagination into the underlying lamina propria lined by a single layer of columnar epithelial cells. Under homeostatic conditions, the majority of crypt cells migrate towards the top of the luminal sur face over the course of approximately a week, after which they are shed in the lumen 74 . Migration out of the crypt base is associated with differentiation into specialized cell types, including absorptive enterocytes and sup porting secretory cell lineages 75 . These differentiated cells are continuously replenished by a small number of multi potent stem cells located in the base of each crypt, known as the stem cell niche 76 . In the presence of injury to this actively cycling stem cell pool, cells from further up the crypt axis fall into the crypt base and regain active stem cell properties 77 . Carcinogenic mutations probably first start accumulating in the longlived stem cell line ages of the crypt, as the lifespan of nonstem cells is too short for them to acquire the necessary mutations before being shed. Although LGR5 + crypt base stem cells are clearly implicated in mutantAPCdriven spor adic CRC and familial adenomatous polyposis 78 , the precise stem cell(s) of origin in IBDdriven neoplasia remains undefined.
Stem-cell-level evolution
Clonal expansion in the colon begins with the progeny of a mutant cell repopulating an entire crypt in a process referred to as monoclonal conversion of the crypt 79 . Even in the absence of any mutant cells, the stem cells in a crypt are randomly lost and replaced by a neighbour ing stem cell lineage in a process called drift. This process eventually results in extinction of all stem cell popula tions except for those originating from the one 'lucky' stem cell clone that repopulates the whole crypt, in a process referred to as niche succession 79 . Some mutations generated in IBD will bias the com petition between stem cells to make it more likely that a particular mutant stem cell will go on to repopulate the entire crypt. In vivo lineage tracing studies of intestinal crypt cells in recombinant mouse models have been used to measure the advantage of tumorigenic mutations. Although a wildtype stem cell will replace another wild type stem cell 50% of the time, in keeping with neutral competition 80, 81 , a stem cell with a Kras mutation will replace a wildtype neighbour stem cell in ~75% of com petitive divisions 81 . Interestingly, Tp53 mutations confer no substantial competitive advantage in a healthy crypt: these mutant cells will replace wildtype cells only 50% of the time 81 . However, in the context of chemically induced colitis (via DSS treatment), Tp53 mutation increases the odds of lineage replacement to 58% 81 . The differing fate of Tp53 mutations in an inflamed crypt compared with a noninflamed crypt reflects the unique selective pressures that exist in the inflamed bowel.
In the healthy bowel, tight morphogen gradients gen erated by cells in and adjacent to the crypt 82 restrict the size of the stem cell niche, keeping stem cell numbers constant 80 . The epithelial wounding that is a hallmark of colitis clearly disrupts these signalling gradients 70, 82 . Additionally, a study in transgenic mice shows how the inflammationmediated NFκB pathway can induce dedifferentiation of nonstem cells, thereby increasing the size of the pool of longlived cell lineages that can contribute to carcinogenesis 43 . Although the precise mechanisms of morphogen gradient disruption are yet to be characterized in human tissue, the altered cellular composition of the supportive pericryptal fibroblasts in Nature Reviews | Gastroenterology & Hepatology The accelerated rate of clonal evolution seen in IBD might be explained by differences between normal and inflamed mucosa. a | In the normal colon, a random mutation generated within a crypt stem cell (first image, in red) results in an advantageous phenotype that eventually results in the extinction of wild-type stem cells (second image). Eventually, all cells of that crypt are formed by progeny of this mutant cell (monoclonal conversion of a crypt). These same mutations often accelerate crypt fission (third image), which is the main mechanism for clonal expansion in the intestine (fourth image). b | In IBD, the altered microenvironment generates epithelial cells with different mutant signatures (red, first image) compared with the normal colon. Active disease provides a selective advantage for those mutant cells that can survive an inflammatory insult (second image). The subsequent healing process selects for those clones that can more rapidly repopulate the mucosa (third image). In this manner, IBD accelerates clonal evolution and expansion (fourth image).
colitis is a notable example of a niche structure alter ation 83 that has been associated with neoplastic progres sion in IBD 84 . Understanding the altered morphogen gradients in IBD is key to understanding how and why particular mutant cells have an evolutionary advantage in IBD.
Crypt-level evolution
Once a mutant clone has repopulated an entire crypt, further clone expansion is possible by crypt fission, the mechanism by which human colonic crypts divide 79 . Thus, the initial celllevel evolution within the crypt switches to cryptlevel evolution and, therefore, natural selection of the crypt population drives field canceriza tion. Crypt fission is the main driver of clonal expan sion in the human colon 85 ; indeed, the fission of crypts surrounding a wound is the primary mechanism of epi thelial restitution in the intestine 70 . Our understanding of the mechanistic drivers of fission is surprisingly lack ing 74 . 3D imaging studies suggest a critical role for the relative arrangement of stem cells and their supportive nicheproviding Paneth cells 86 , and mathematical model ling indicates that a plausible mechanism for triggering fission is exceeding a threshold number of stem cells 87 . Crypt fission is a mechanism for mucosal healing 70 , and the increase in frequency of cryptfission events in the IBD bowel is a reflection of the wounding or repair that is characteristic of the disease. Cheng and col leagues 88 found that, although <1 in 200 crypts in nor mal human colon are undergoing fission, this rate was increased at least 60fold in IBD. Mutations that increase the rate of crypt fission are probably positively selected for in the IBD bowel, as these mutants are better able to heal the damaged mucosa. In line with this hypothesis, mutant Kras crypts divide 30fold faster than their wild type counterparts in the mouse intestine 89 , and Tp53 mutation is also reported to increase the crypt fission rate in mice 90 . Thus, it is reasonable to expect that some mutants which undergo substantial clonal expansion and populate multiple crypts in the nonneoplastic epithe lium achieve this expansion by the acquisition of muta tion(s) that positively regulate crypt fission (FIG. 1) . This selection for mucosal healing rather than neoplasia per se might be the underlying reason for the common occur rence of flat dysplastic lesions in IBD. Consequently, in our opinion, we believe that assessing the inflamed epi thelium for clonally expanded mutations offers a 'natural experiment' that can be exploited to identify new genes that modulate crypt fission. This novel approach recog nizes one of the old adages of cancer biology: the overlap between wound healing and carcinogenesis 91 .
Other potential mechanisms
One intriguing finding from IBD mapping studies is the detection of mutant populations containing the exact same point mutation (single nucleotide variant) or copy number alteration (CNA), extending across most of the colon length 25, 92 . Although pancolonic selection pressures could plausibly select for the same altered cel lular or crypt functions repeatedly through convergent evolution, inducing the exact same point mutation is highly unlikely and so the very large mutant populations observed are likely to be clonal in origin. Additionally, how mucosal repopulation by fission of adjacent crypts alone could explain the same mutation spread across the entire bowel in a matter of a few years is difficult to comprehend. These findings raise the possibility of unidenti fied healing mechanisms in colitis. Mouse model studies show that freefloating organoids intro duced intra luminally can successfully engraft on to an inflamed bowel to generate longlasting functional crypt populations, but not in the context of a non inflamed colon 93 . In light of the phenotypic elasticity of multiple crypt cell populations and the rapid rate of epithelial shedding in active IBD, this finding raises the intriguing possibility of longrange stem cell migration following shedding and distant stem cell reengraftment. However, to date, no evidence exists for this speculative healing mechanism in human studies or in IBD animal models. Conversely, precedence for this process in other model organisms does exist; longdistance stem cell migra tion has been noted to occur between widely separated ovarian follicles in Drosophila
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Evolutionary management of cancer risk Predicting cancer risk in IBD
Great interest exists for the development of cancer biomarkers in IBD 95 , with DNA aneuploidy 96 and/or TP53 mutations 64, 97, 98 as the most prominent examples of genetic biomarkers. However, extensive within lesion genetic and phenotypic heterogeneity are now considered hallmarks of both carcinogenesis 99 and pre malignant pathology 22 . Indeed, in the pre malignant disease, Barrett oesophagus, which confers a ~30fold increased risk of developing oesophageal adeno carcinoma 100 , sequencing studies of biopsies from non neoplastic Barrett segments demonstrate cancerrelated mutations in a plethora of different genes. With the exception of TP53, these mutations occur at similar frequencies across nondysplastic through to highgrade dysplasia and even adeno carcinoma tissues 101 . In spor adic CRC, largescale sequencing projects reveal only seven genes that are recurrently mutated in >10% of patients, meaning that the overwhelming majority of mutations were unique to small subsets of patients 71 . Collectively, these data indicate the improbability that a single gene or small set of genetic changes can effectively assay the vast array of different molecular pathways that lead to cancer 102 , so it is unlikely that traditional candidate gene biomarker approaches will yield clin ically applicable prognostic biomarkers. Nevertheless, as the cost of sequencing continues to decrease, the option to costeffectively sequence a relatively large panel of genes that encompass all the key pathways involved in CACRC development (once these have all been identi fied) could well be a possibility -such an approach already shows promise in acute myeloid leukaemia 103 . A different approach involves looking for robust prog nostic biomarkers from measurements of the under lying evolutionary process itself. The rationale here is that, although the evolutionary paths might differ between patients, limiting the efficacy of candidategenebased studies, somatic evolution is always subject to the same rules and the selective pressures of an inflamed bowel are similar across patients. Thus, biomarkers based upon measurements of these evolutionary rules could have universal applicability.
One example of a candidate 'evolutionary biomarker' is clonal diversity. In ecological studies, the level of diversity in a population is a major determinant of its evolvability 104 . If there is no diversity, natural selection cannot operate, whereas diverse populations are likely to adapt and evolve quickly. Translated to IBD, the clonal diversity within the bowel is a potential evolutionary biomarker of cancer risk and, notably, measuring clonal diversity requires no substantial prior knowledge of the precise genetic and epigenetic pathways driving tumori genesis. To date, no studies have used genetic diversity measures for CACRC risk, but the principle has pre viously been applied to Barrett oesophagus. Genetic diversity measures were predictors of cancer risk even after controlling for age, Barrett segment length, TP53 mutation and aneuploidy status 105 , and were robust to the molecular assay used to detect diversity 106 . A second approach that also reflects evolvability would be detec tion of large clonal expansions as a measure of ongoing evolution. Preliminary studies in patients with ulcer ative colitis found progressors (highgrade dysplasia or cancer) have substantially larger clonal expansions than nonprogressors, by using 4-5 biopsies (spaced ~20 cm apart) for the detection of mutant clones with shared point mutation(s) 107 . This work highlights a promising avenue to explore. Additionally, changes over time in the clonal composition of the epithelium might also be prognostic, irrespective of what those changes might be, because they are also an indicator of ongoing evolu tion. In Barrett oesophagus, neoplastic initiation seems to be abrupt, but single nucleotide polymorphism array studies suggest that considerable discriminating changes in clonal composition occur 24 months before oesoph ageal adenocarcinoma detection 108 . Finally, analys ing changes in immune, mesenchyme and/or microbiota microenvironmental composition (which form the basis for future evolution), and/or their modu lation by the epithelial cells themselves 109 , offers yet another approach. Concomitant genomic-microenvironmental evolutionary studies could also help answer a 'chicken andegg' question in CACRC: which came first, the altered microenvironment that predisposes to cancer risk, or the predisposed clones themselves?
Use of surveillance biopsies In our opinion, IBDassociated cancer surveillance is an ideal 'model system' in which to study in vivo inflammationassociated carcinogenesis in humans. Multiple biopsies are routinely taken at each surveil lance colonoscopy and subjected to histological assess ment for inflammation severity and endo scopically invisible dysplasia. This process creates an extensive tissue library of archival specimens reflecting the spatio temporal clonal evolutionary changes that occur during carcinogenesis. Thus, this rich resource can be utilized to better understand the biology of the intestine and how it is subverted during cancer development. The spatial distribution of genetic alterations across surveillance biopsies indicates the order of mutations that led to the current clone composition: a 'trunk' or 'founder' mutation present in all biopsies arose before a 'branch' mutation that is limited to a subset of biopsies. A phylogenetic analysis of multiple biopsies at a single timepoint (from an individual endoscopy) provides a mechanism for inferring the pattern of genetic changes over space and time.
Several studies have used mapping biopsies to analyse the spatiotemporal changes in clonal popula tions, including the relationship between CNAs and key gene mutations. In early studies, analysis of ulcerative colitis colonoscopic biopsy specimens taken over an 8year period using flow cytometry showed that aneu ploidy can be detected before the onset of dysplasia in at least 10% of patients, with CNAs becoming more widespread over time in a subset of patients 110 . TP53 gene mutations can also be found in morphologically normal mucosa and correlate strongly with the presence of aneuploidy 64 . TP53 loss of heterozygosity was found more commonly in dysplasia, suggesting that it might be a later event 111 . Longitudinal analysis of three patients with Crohn's disease using targeted sequencing of TP53, KRAS and CDKN2A revealed that some cancer cases had arisen from a field of mutant clones that expanded well beyond the cancer resection margin and formed many years before cancer growth 25 . Similarly, largescale regional clonal expansions were associated with cancer occurrence in a study that used hypermutable non coding polyguanine tracts as neutral lineage markers to trace clonal expansions across colectomy specimens 107 . A genomewide comparative genomic hybridisation array study found that CNAs of chromosomal segments are present in most colons with pancolitis, and are at increased frequency in those with neoplasia, without left or right colon bias 92 . Interestingly, this study reported that most CNAs (~85%) were unique to a single biopsy (with substantial differences detected in CNA profiles from biopsies as little as 2 cm apart) with no shared CNAs between highgrade dysplasia and cancer, and the non dysplastic surrounding mucosa. This finding suggests that genetic field cancerization does not universally precede cancer development, and instead some patients show focal genetic instability. Consequently, the detection of these different occult evolutionary processes, includ ing selective mutant sweeps (in which a clone grows to cover very large segments of the colon) and pancolonic genomic instability (in which multiple different mutant clones arise independently at different location), might provide an indicator for CACRC development risk.
Optimizing screening intervals
Endoscopic screening intervals (the time between suc cessive endoscopies) could potentially be optimized by an underlying knowledge of the spatiotemporal dynam ics of clonal evolution occurring in IBD. The reason is straightforward: if the minimum time it will take for a cancer to evolve from the current composition of the bowel is known, surveillance can be planned accordingly.
Our current knowledge of the rates of clone growth in the inflamed bowel is minimal. Basic questions, such as the duration of time required for a clone to undergo expansion substantial enough to be detectable with biopsy, and the time required to establish a mutant cancerization field, remain unanswered. Moreover, the rate and consistency of mutation accumulation is unknown. In our opinion, measuring these funda mental evolutionary parameters could have direct clinical relevance.
A practical factor to consider when using IBD sur veillance is the fidelity of standard mapping biopsies at reflecting true clonal composition of the entire colon.
Routine colonoscopic biopsies contain ~200 crypts 112 . Owing to the sheer length of the whole colon, even the most intensive IBD mapping biopsy protocols sample <1% of the colonic mucosal surface 113 . Thus, endoscopy based studies might result in considerable clonal popu lations being missed, unless clonal patch sizes truly are often as large as those detected in some patients with IBD 25, 92 . Understanding the clonal mosaicism of the bowel could help guide optimal biopsy protocols. Moreover, as ulcerative colitis by definition starts in the rectum and extends proximally, we speculate that the rectum is the site where the most evolution has occurred, suggesting that the evolutionary dynamics in the distal * * With ongoing inflammation, a cancer forms more proximally (right panel) and a proctocolectomy might be considered. Here, large-scale and/or rapid clonal expansion of cancer-associated mutations could be a biomarker of high cancer risk. c | In IBD progression through clonal mosaicism, multiple distinct clonal populations develop and progress throughout the colon. The end result is two cancers and a dysplastic region, all arising in the left colon, without sharing the same 'truncal' genomic changes. In the absence of large clonal fields, a diagnosis of a 'dangerous' clone is challenging. However, high levels of clonal mosaicism and substantial changes over time indicate 'active evolution' that could be utilized as a biomarker of cancer risk.
colon might have the most relevance for disease aetio logy. Indeed, preliminary evidence raises the possibility that chromosomal instability of the rectum is a proxy marker of CRC risk for the whole large intestine 114 . Nevertheless, this approach might not apply for patients with Crohn's disease and socalled skip lesions, or for patients with primary sclerosing cholan gitis and with a propensity to develop rightsided colon cancer owing to possible aberrant enterohepatic biliary circulation 115 . Assessing the evolutionary dynamics of the colon would enable us to define the window of opportunity for cancer risk prognostication, rationalize colonoscopic biopsy protocols (random versus segmental versus endo scopic areas of concern) and determine the appropriate time intervals between endoscopies (FIG. 2) . To ensure clinical utility, such a biomarker should aim for maximal sensitivity to avoid missing cancer cases.
Managing neoplastic lesions
Managing dysplasia remains the most challenging clin ical dilemma in IBD surveillance. Differentiating those patients requiring immediate colectomy from those who can be safely managed conservatively remains difficult. Consensus guidelines based on dysplasia morphology and endoscopic resectability aim to standardize clinical approaches 116 . Although the majority of patients with lowgrade dysplasia will never develop cancer, 25% of patients with lowgrade dysplasia who are advised to undergo colectomy will already have an established cancer in their surgical specimen 11 . Even when a cancer is detected at colonoscopy, it is not uncommon for patients to request a segmental resection rather than proctocolectomy, to avoid living with a stoma and/or ileo anal pouch. Such requests go against standard clin ical advice; at least onethird of patients undergoing colectomy for CACRC detected at surveillance will have a second synchronous neoplastic region 11 . Dysplastic lesions offer an ideal opportunity to assess the utility of evolutionary biomarkers by localizing the site of a mutant cancerization field (FIG. 2) . These lesions and the surrounding mucosa can then be assessed for markers of somatic evolution, such as the local burden of genomic alteration (or mutational burden). The sizes of clonally expanded patches and the degree of clonal diversity might enable identification of highrisk lesions that are likely to progress to CRC. This application is particularly useful for patients with recurrent, invisible or nonresectable lowgrade dysplasia, whereas evolu tionary markers associated with a high risk of cancer development could be used as an indication for colec tomy. Furthermore, analysing the remaining mucosa to determine the spatial extent of these highrisk changes might enable identification of a subset of patients with limited cancerization field changes, who could be offered a segmental colectomy that preserves anorectal function.
Optimizing treatment to prevent cancer
With inflammation a key driver of CACRC risk in clin ical and laboratory studies, assessing how therapy modu lates occult evolution provides a means to understanding how and why drug treatments affect cancer develop ment. Aspirin reduces both sporadic CRC incidence 117 and precursor adenoma recurrence 118 , and evidence from Barrett oesophagus shows that NSAID use slows the rate of somatic mutation accumulation 119 , suggesting an evolutionary mechanism of cancer prevention. Together, these data imply that attenuation of inflammation can have profound influence on the carcinogenic process. Nevertheless, although drug treatment in patients with IBD might modulate clonal evolution of the inflamed bowel 120 , similar studies assessing evolution patterns before and after therapy are needed to define and rational ize the most optimal medical intervention strat egy. As a clear majority of patients undergoing cancer surveillance show some evidence of active inflammation on biopsy 121 , these studies might generate greater clinical impetus towards achieving deep remission 122 in highrisk patients, rather than symptomatic relief alone.
Conclusion
Occult evolution is a feature of IBDassociated carcino genesis and begins long before the development of clinically detectable neoplasia. Repeated episodes of inflammation generate mutant clones and select for those cells best adapted to this microenvironment, such as clones resistant to apoptosis and those with acceler ated growth. These selective pressures, unique to IBD, might explain the unique characteristics of IBDassociated neoplasia in comparison to its sporadic counter part. Assaying this evolutionary process is an exciting new opportunity for developing a new class of biomarkers that are robust to the stochastic nature of tumorigenic mutations, which has hampered the effective ness of traditional candidategene biomarkers. For clinicians, such a marker would not only aid in cancer risk stratifi cation, but might even identify those patients requir ing surgery for dysplasia and/or cancer who would be candidates for segmental resection rather than procto colectomy, thereby preserving some colo rectal function. For cancer biologists, the IBD surveillance protocol is an underutilised model for understanding human intestinal biology.
